Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Parallel Controlled, Double-blind Clinical Trial Designed to Evaluate the Efficacy and Safety of Hymecromone Tablets in Subjects Diagnosed With COVID-19 Infection.

NCT05386420 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT05386420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05386420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Parallel Controlled, Double-blind Clinical Trial Designed to Evaluate the Efficacy and Safety of Hymecromone Tablets in Subjects Diagnosed With COVID-19 Infection.
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 23, 2022
Completion date
November 15, 2022
Enrollment
304 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19